InnoCare, Eli Lilly Sign Research And Licensing Deal Worth Up To $3.35 Billion

Beijing-based cancer drug developer InnoCare Pharma said on Thursday it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion.

Deal points to a broader shift

Analysts said the transaction highlights a move by China’s biotech firms towards bigger partnerships, with deal making evolving beyond the licensing of individual drug candidates.

The latest transaction underscores that shift as China’s biotech sector transforms from a follower into what analysts described as a global innovation leader.

InnoCare’s pact with Eli Lilly is therefore being read not only as a single company agreement, but also as part of a wider change in how Chinese biotech companies are engaging with global pharmaceutical groups.

What the companies disclosed

InnoCare said it would use its drug discovery platform to identify and advance compounds against up to five targets.

The companies did not disclose the specific therapeutic areas covered by the partnership.

They said only that the new drugs would seek to “address critical unmet medical needs”.

The agreement combines research collaboration with licensing, placing it beyond a simple licensing arrangement for one drug candidate.

For analysts, the potentially US$3.35 billion value of InnoCare’s agreement with Eli Lilly reflects the increasing scale of such partnerships involving Chinese biotech firms.

Source: South China Morning Post